HYPERCAPNIA

Phase 2Biologic

UUniversity Hospital, Clermont-Ferrand

HYPERCAPNIA is one of 5 biologic programs targeting Ischemic Stroke, Acute. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic Stroke, AcuteRecruiting

Ischemic Stroke, AcutePhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Ischemic Stroke, Acute

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

1 2

Aggrastat

MMedicure

Approved

1 3

Alteplase or Tenecteplase

CChinese University of Hong Kong

Phase 3

1 4

Non-Immunogenic Staphylokinase

SSupergene, LLC

Phase 3

1 5

HYPERCAPNIA

UUniversity Hospital, Clermont-Ferrand

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Ischemic Stroke, Acute

NCT05051397

Clinical

Trials by Indication[1]

Ischemic Stroke, Acute1 trial

Evaluation of the Effect of Moderate and Controlled Hypercapnia on Ischemic Penumbra Vascular Collaterality During General Anesthesia for Anterior Circulation Acute Ischemic Stroke Mechanical Thrombectomy

Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT05051397·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HYPERCAPNIA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HYPERCAPNIA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HYPERCAPNIA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Clermont-Ferrand

HYPERCAPNIA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ischemic Stroke, Acute1 trial

References

Drug Info

Quick Facts

Related News